Roche Holding AG

ROG

CH0012032048

Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.

Employees

103,605

Sector

Pharmaceuticals

Calendar

13/09/2024 - European Association for the Study of Diabetes Meeting

Related indices

SMI , STOXX Europe 600 Index (EUR)

More about the company

Income Statement and Estimates

More financial data

Analysis / Opinion

ROCHE HOLDING : Strong Q2 led to a guidance upgrade

July 25, 2024 at 05:00 pm

Obesity: Roche joins the battle

December 04, 2023 at 03:48 pm

More Strategies

Ratings

Trading Rating

Investor Rating

ESG Refinitiv

A+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

268.80CHF

Average target price

298.00CHF

Spread / Average Target

+10.86%

Consensus

Profit revisions

Estimate revisions

Quarterly earnings, Rate of surprise

Company calendar

Market Closed - Swiss Exchange Other stock markets 16:30:27 11/09/2024 BST			5-day change	1st Jan Change
268.80 ^CHF	-0.04%		-3.72%	+9.94%

09-11	The mood is getting heavier, but Taylor Swift is keeping watch
09-10	Weight-loss market to see 16 new drugs by 2029, report estimates	RE

The mood is getting heavier, but Taylor Swift is keeping watch	09-11
Weight-loss market to see 16 new drugs by 2029, report estimates	09-10	RE
ROCHE HOLDINGS AG : UBS remains Neutral	09-10	ZD
Roche Opens New Research Center in Switzerland	09-10	MT
Roche inaugurates R&D center in Basel	09-10	CF
ROCHE HOLDINGS AG : Goldman Sachs reiterates its Sell rating	09-10	ZD
ROCHE HOLDINGS AG : Deutsche Bank reiterates its Neutral rating	09-10	ZD
ROCHE HOLDINGS AG : JP Morgan maintains a Sell rating	09-09	ZD
ROCHE HOLDINGS AG : Gets a Neutral rating from UBS	09-09	ZD
Swiss Market Index Kicks Off ECB Rate Decision Week in Green	09-09	MT
Moody's Affirms Roche's Ratings on Strong Business Profile	09-09	MT
The market burns its idols	09-09
Roche: AI to enrich cancer diagnostics	09-09	CF
AstraZeneca Partners with Roche Unit on Non-small Cell Lung Cancer Biomarker Diagnostic Companion	09-09	MT
Swiss Stocks End Week in Red; All Eyes on US Jobs Report	09-06	MT
ROCHE HOLDINGS AG : Berenberg sticks Neutral	09-06	ZD
ROCHE HOLDINGS AG : JP Morgan reiterates its Sell rating	09-06	ZD
Swiss Equities Remain in the Red Amid Regional Retreat	09-04	MT
Roche: new positive data for fenebrutinib	09-04	CF
Roche's Investigational Multiple Sclerosis Drug Shows Disease Activity Suppression in Mid-stage Trial	09-04	MT
Roche's Fenebrutinib Demonstrates Near- Complete Suppression of Disease Activity and Disability Progression for Up to 48 Weeks in Patients with Relapsing Multiple Sclerosis	09-04	CI
ROCHE HOLDINGS AG : JP Morgan maintains a Sell rating	09-03	ZD
ROCHE HOLDINGS AG : Bernstein maintains a Buy rating	08-29	ZD
Swiss Equities Close in the Red; Roche Sheds 1%	08-27	MT
Roche: approval from Brussels for HPN	08-27	CF

Roche Holding AG

Equities

ROG